JP2021525068A5 - - Google Patents

Info

Publication number
JP2021525068A5
JP2021525068A5 JP2020564250A JP2020564250A JP2021525068A5 JP 2021525068 A5 JP2021525068 A5 JP 2021525068A5 JP 2020564250 A JP2020564250 A JP 2020564250A JP 2020564250 A JP2020564250 A JP 2020564250A JP 2021525068 A5 JP2021525068 A5 JP 2021525068A5
Authority
JP
Japan
Prior art keywords
manipulated
cell
immune cells
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020564250A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525068A (ja
JP7584299B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/033836 external-priority patent/WO2019226945A1/en
Publication of JP2021525068A publication Critical patent/JP2021525068A/ja
Publication of JP2021525068A5 publication Critical patent/JP2021525068A5/ja
Priority to JP2024074968A priority Critical patent/JP2024109634A/ja
Application granted granted Critical
Publication of JP7584299B2 publication Critical patent/JP7584299B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020564250A 2018-05-23 2019-05-23 T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現 Active JP7584299B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024074968A JP2024109634A (ja) 2018-05-23 2024-05-02 T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862675511P 2018-05-23 2018-05-23
US62/675,511 2018-05-23
PCT/US2019/033836 WO2019226945A1 (en) 2018-05-23 2019-05-23 Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024074968A Division JP2024109634A (ja) 2018-05-23 2024-05-02 T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現

Publications (3)

Publication Number Publication Date
JP2021525068A JP2021525068A (ja) 2021-09-24
JP2021525068A5 true JP2021525068A5 (cg-RX-API-DMAC7.html) 2022-05-24
JP7584299B2 JP7584299B2 (ja) 2024-11-15

Family

ID=68617219

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020564250A Active JP7584299B2 (ja) 2018-05-23 2019-05-23 T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
JP2024074968A Pending JP2024109634A (ja) 2018-05-23 2024-05-02 T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024074968A Pending JP2024109634A (ja) 2018-05-23 2024-05-02 T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現

Country Status (9)

Country Link
US (1) US12129485B2 (cg-RX-API-DMAC7.html)
EP (1) EP3784776A4 (cg-RX-API-DMAC7.html)
JP (2) JP7584299B2 (cg-RX-API-DMAC7.html)
KR (2) KR20210008408A (cg-RX-API-DMAC7.html)
CN (1) CN112166185A (cg-RX-API-DMAC7.html)
AU (1) AU2019275076B2 (cg-RX-API-DMAC7.html)
CA (1) CA3100386A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202010996QA (cg-RX-API-DMAC7.html)
WO (1) WO2019226945A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7584299B2 (ja) * 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現
CA3119296A1 (en) * 2018-11-14 2020-05-22 Medisix Therapeutics Pte Ltd. Two-gene vectors for generating car-t cells and uses thereof
CA3207206A1 (en) * 2021-02-01 2022-08-04 Lingfeng LIU Targeted protein degradation system and use thereof
WO2023159108A1 (en) * 2022-02-16 2023-08-24 Gentibio, Inc. Cd2-binding and cd28-binding membrane-bound polypeptides and uses thereof for evading host immune response
WO2023220457A1 (en) * 2022-05-13 2023-11-16 Northwestern University Receptor engagement-mediated enhancement of biologics delivery

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB2338237B (en) 1997-02-18 2001-02-28 Actinova Ltd In vitro peptide or protein expression library
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
JP2001516766A (ja) 1997-09-19 2001-10-02 デイナ−ファーバー キャンサー インスティチュート,インコーポレイテッド 免疫反応の細胞内発現抗体仲介制御
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6794136B1 (en) 2000-11-20 2004-09-21 Sangamo Biosciences, Inc. Iterative optimization in the design of binding proteins
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
WO2002072600A2 (en) * 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
CA2461290C (en) 2001-09-24 2014-11-25 Sangamo Biosciences, Inc. Modulation of stem cells using zinc finger proteins
WO2003051926A2 (en) 2001-12-14 2003-06-26 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Anti-cd7 immunotoxin as fusion protein
DK1578446T3 (en) * 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
HRP20120845T1 (hr) 2003-07-02 2012-11-30 Innate Pharma Protutijela za pan-kir2dl nk-receptor i njihova uporaba u dijagnostici i lijeäśenju
US20090191213A9 (en) 2003-07-02 2009-07-30 Novo Nordisk A/S Compositions and methods for regulating NK cell activity
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
WO2005017163A2 (en) 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
CA2601417C (en) 2004-07-01 2018-10-30 Novo Nordisk A/S Human anti-kir antibodies
WO2006003179A2 (en) 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
US20060121043A1 (en) 2004-10-27 2006-06-08 Medimmune, Inc. Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections
US20090196850A1 (en) 2005-01-06 2009-08-06 Novo Nordisk A/S Anti-Kir Combination Treatments and Methods
US20070036773A1 (en) 2005-08-09 2007-02-15 City Of Hope Generation and application of universal T cells for B-ALL
JP4860703B2 (ja) 2005-10-06 2012-01-25 ゼンコー・インコーポレイテッド 最適化された抗cd30抗体
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
EP2185574B1 (en) 2007-09-07 2013-05-08 Agensys, Inc. Antibodies and related molecules that bind to 24p4c12 proteins
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
WO2013006490A2 (en) * 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
ES2728782T3 (es) 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
KR20150029714A (ko) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강
PL4019041T3 (pl) 2012-07-13 2023-05-08 The Trustees Of The University Of Pennsylvania Kontrola toksyczności wobec aktywności przeciwnowotworowej CAR
WO2014059173A2 (en) 2012-10-10 2014-04-17 Sangamo Biosciences, Inc. T cell modifying compounds and uses thereof
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
KR101521224B1 (ko) 2012-12-20 2015-05-19 한양대학교 산학협력단 T 세포 특이적인 인간화 단일조각항체 전달체
AU2013370210B2 (en) 2012-12-27 2018-06-14 Aduro Biotech, Inc. Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof
SG11201507026WA (en) 2013-02-06 2015-10-29 Anthrogenesis Corp Modified t lymphocytes having improved specificity
US11311575B2 (en) 2013-05-13 2022-04-26 Cellectis Methods for engineering highly active T cell for immunotherapy
JP6608807B2 (ja) 2013-05-29 2019-11-20 セレクティス Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法
EP3858379A1 (en) 2013-11-21 2021-08-04 Autolus Limited Cell
DK3105317T3 (en) 2014-02-14 2019-01-14 Cellectis Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells
GB201405845D0 (en) 2014-04-01 2014-05-14 Ucl Business Plc Signalling system
IL292038B2 (en) 2014-04-23 2024-12-01 Juno Therapeutics Inc Methods for enriching or producing immune cell populations for adoptive therapy
US10738278B2 (en) 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
AU2015330017A1 (en) 2014-10-07 2017-04-27 Cellectis Method for modulating car-induced immune cells activity
HRP20240357T1 (hr) 2014-12-24 2024-06-07 Autolus Limited Stanica
HRP20220890T1 (hr) 2015-02-06 2022-10-14 National University Of Singapore Postupci za povećanje učinkovitosti terapijskih imunosnih stanica
CA2977106A1 (en) 2015-02-27 2016-09-01 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
BR112017018770A2 (pt) 2015-03-02 2018-04-17 Innovative Cellular Therapeutics CO., LTD. redução da tolerância imunológica induzida por pd-l1
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
KR102349677B1 (ko) 2015-05-28 2022-01-12 카이트 파마 인코포레이티드 T 세포 요법을 위해 환자를 컨디셔닝하는 방법
ES2860710T3 (es) * 2015-07-13 2021-10-05 Centre Hospitalier Univ Vaudois Chuv Inhibidores de IL-26
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
KR102908806B1 (ko) 2015-10-22 2026-01-07 주노 테라퓨틱스 게엠베하 세포의 배양 방법 및 이를 위한 키트와 장치
CN108463547A (zh) 2015-10-28 2018-08-28 生命技术股份公司 通过改变细胞表面信号和信号比选择性扩增不同的t细胞亚群
US11390658B2 (en) 2016-06-06 2022-07-19 St. Jude Children's Research Hospital Anti-CD7 chimeric antigen receptor and method of use thereof
CA2937157A1 (en) 2016-07-25 2018-01-25 Ucl Business Ltd Protein-based t-cell receptor knockdown
US12350349B2 (en) * 2016-08-03 2025-07-08 Washington University Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
WO2019226946A1 (en) 2018-05-23 2019-11-28 National University Of Singapore Chimeric antigen receptors and gene editing of cd2 for immunotherapy of t-cell malignancies
JP7584299B2 (ja) * 2018-05-23 2024-11-15 ナショナル ユニバーシティ オブ シンガポール T細胞悪性腫瘍の免疫療法のためのcd2表面発現の遮断およびキメラ抗原受容体の発現

Similar Documents

Publication Publication Date Title
Dai et al. Chimeric antigen receptors modified T-cells for cancer therapy
JP2023515211A5 (cg-RX-API-DMAC7.html)
JP2020509767A5 (cg-RX-API-DMAC7.html)
CN118546959A (zh) Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
US11970545B2 (en) T cell-antigen coupler with Y182T mutation and methods of uses thereof
CN113227379A (zh) 多功能多靶向嵌合抗原受体(car)系统及其使用方法
US20230210905A1 (en) T cell-antigen coupler with various construct optimizations
JP2018516092A5 (cg-RX-API-DMAC7.html)
JP7404279B2 (ja) 様々な構築物最適化を備えたt細胞抗原カプラ
CN109952309A (zh) 用于细胞治疗的组成型活性细胞因子受体
JP2017523784A5 (cg-RX-API-DMAC7.html)
JP2023500338A5 (cg-RX-API-DMAC7.html)
JP2016520074A5 (cg-RX-API-DMAC7.html)
US12466869B2 (en) Targeting of multiple antigens with multiplex CAR T cells in solid and liquid malignancies
WO2018200713A1 (en) Compositions and methods for targeted tumor immunotherapy
CN106459990A (zh) 三功能t细胞抗原偶联物及其制备方法和用途
JP2021525067A5 (cg-RX-API-DMAC7.html)
US20240016841A1 (en) Cells comprising t cell-antigen couplers and uses thereof
JP2022553292A5 (cg-RX-API-DMAC7.html)
JP2024540275A5 (cg-RX-API-DMAC7.html)
CN112442509A (zh) Cd19-cd20双特异性和双通道car-t及其使用方法
WO2024012457A1 (zh) 三特异性抗体及其用途
JP2026501506A (ja) Cldn18.2及びcd3に結合する二重特異性結合剤並びに免疫チェックポイント阻害剤を含む併用療法
EP1666500B1 (en) Use of trifunctionel antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy
EP3986443A1 (en) Combination cancer immunotherapy